Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AB-110 in Adults With Hematologic Malignancies Undergoing Cord Blood Transplantation
NCT03483324Phase 1Completed
- Sponsor
- Angiocrine Bioscience
- Start
- Apr 2018
- Primary completion
- Dec 2020
- Modality
- Gene Editing, Gene Silencing, Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of AB-110 in acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), myelodysplastic syndrome (MDS) and 1 more, sponsored by Angiocrine Bioscience. Primary endpoints: Occurrence of adverse events grade 4 or grade 5 at 24 hours and Graft failure at 42 days. Started Apr 2018; status: completed.
02
Drugs
AB-110
03
Conditions
acute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)myelodysplastic syndrome (MDS)acute leukemia
Beyond the preview
Go deeper on NCT03483324.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03483324.